Allurion expects FY25 net sales of 15M [Seeking Alpha]
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
Allurion Technologies (NYSE:ALUR) had its "neutral" rating reaffirmed by analysts at Chardan Capital. They now have a $2.50 price target on the stock.